In acute myeloid leukemia (AML), UCA1 can be used as an endogenous sponge to compete with miR-126, which in turn suppresses activation of the PI3K/AKT signaling pathway by inhibiting the expression of RAS-related C3 botulinus toxin substrate 1 (RAC1) (62). The gene discussed is AKT1; the disease is acute myeloid leukemia.